People · Operator
Named in public records as an officer, director or promoter · active 2010–2018 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Insmed Inc | — | Biotechnology | Series C | $83.7M | $3.4B | 2010 |
| Ammonett Pharma LLC | — | Pharmaceuticals | Seed | $2.4M | $90.7M | 2018 |
Kevin P. Tully at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin P. Tully on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel J. O'Connell | 1 | 3 |
| Donald Hayden, Jr. | 1 | 3 |
| Steinar Engelsen | 1 | 2 |
| Randall Whitcomb | 1 | 2 |
| John O. Brooks | 1 | 1 |
| Nicholas P LaBella | 1 | 1 |
| Melvin Sharoky | 1 | 1 |
| Renu P Gupta | 1 | 1 |
| Timothy P Whitten | 1 | 1 |
| Michael O. Thorner | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.